gum downgrad cl neutral
buy
tougher comp share loss take breather
downgrad cl neutral buy today prior posit view
predic turnaround cl improv organ sale growth launch
meaning innov two import categori toothpast pet re-
rate continu view cl one higher qualiti name con
stapl domin market share low privat label exposur geograph depth
aggress stanc drive growth struggl stem share loss toothpast
tough comp drive concern condit challeng next year
potenti necessit anoth year outsiz invest hill bright
spot china oral care volatil contrast pg faster
growth yet trade similar valuat believ stori well-understood
level consid cost execut risk revit stubborn busi
competit geographi lower estim higher spend lower
po base target price-to-earnings estim prior
sale growth come cost
organ revenu improv dramat follow challeng
benefit relaunch colgat total strong year hill make
comp difficult could requir invest maintain ep
flat average reflect fx pressur also higher cost compet
cpg consum packag good exacerb shift on-line emerg
local competitor intenational market commod fx pressur look less oner
share loss still persist notabl toothpast despit total
relaunch expect anoth year outsiz invest leav us concern
visibl growth
tracked-channel trend slow late
share weaker key categories/geographi particularli toothpast
cl lost share y/i end consecut month
deceler key emerg market like mexico flat brazil china
consider work local competit keep pressur high
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price
object basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
person household fabric pet nutrit
brand includ ajax fab softsoap palmol
mennen speed stick hill pet nutrit
colgate-palmol product market
continu view cl one higher
qualiti name consum stapl domin
geograph depth aggress stanc
drive growth struggl stem share loss
toothpast tough comp drive concern
condit challeng next year
potenti necessit anoth year outsiz
key point six chart
chart recoveri organ sale growth comp
difficult
chart cl total sf us distribut steadi around
chart cl ntm price-to-earnings expand year
chart cl weight averag share challeng
chart hill solid pet specialti retail growth deceler
intern data aggreg debt credit card spend pet specialti retail
chart though arguabl peer cl ntm price-to-earnings rel stapl
bloomberg note hpc group includ el pg
price-to-earnings rel
downgrad neutral
frame cl path forward growth cost
cl organ sale growth improv four consecut quarter signific
deceler driven new product particularli colgat hill
brand broader leverag portfolio expans new channel brand support
acceler pressur like fx commod inflat becom somewhat
manag ep growth given pass cl step spend
drive improv growth go forward told cl sure foot still-domin
market share compel geograph breadth innov oral care portfolio
expans skincar via nevertheless valuat come notabl
see path continu organ growth momentum hamper tough comp
continu high need reinvest make slower market like china work keep
us go
look compani global share key categori also concern leav us
hesit manag abil sustain revenu growth momentum end
third quarter saw declin share point global toothpast
share year-to-d basi share global manual toothbrush
market share point year-ago period year-to-d
basi well year-to-d market share toothpast flat europ
north america latin america asia pacif africa/eurasia versu compar
period manual toothbrush categori year-to-d market share
europ asia pacif north america latin america africa/eurasia versu
abil sustain top-lin momentum
cl organ sale growth acceler sequenti last four quarter start
decemb better growth driven price volum modest
off-set volum inflect maintain drive
acceler organ sale face strong comp believ continu organ
growth momentum challeng sustain cl part guidanc
organ growth alreadi signal sequenti slowdown believ
sustain organ growth possibl contribut
growth sourc outsid us strengthen asiapac easi comp
continu strength albeit slower africa/eurasia organ
tougher comp make organ growth momentum harder sustain
believ healthi balanc cl organ growth year far rais bar
expect invest need sustain higher level go
forward per manag emerg market develop market grew y/i
cl hub grow organ quarter moreov
composit growth encourag volum price
categori cl compet oral person pet
chart cl organ sale growth build organ sale moder hold
cl total hill scienc diet anchor growth
cl two signific re-launch new variant total toothpast call
total sf revamp scienc diet hill innov
target largest subcategori respect market multi-benefit toothpast
specialti pet food respect
hill cl start roll-out us global roll-out
relaunch success far drive volum growth price
third quarter encourag result follow period increas
spend past year anticip need continu maintain
momentum one area concern mix shift toward scienc diet ahead
prescript diet manag call margin dilut
contribut wide gross margin miss past quarter requir focu
rebal hill relaunch continu global expans said think
grow concern pet food ingredi provid solid backdrop continu
strength hill
total sf roll-out began late north america nielsen-
track channel total sf settl distribut across scan point
price premium cl exist toothpast franchis per nielsen data
concern sf brand overal inabl lift colgat us share total
toothpast data show steep declin temporari lift level
bp cl toothpast share march view us toothpast
area concern requir manag attent stewardship
believ pose risk north america contribut organ growth algorithm
chart cl total sf distribut us track channel
new initi drive distribut resourc intens
addit two key relaunch colgat total sf hill scienc diet note
sever capital-intens initi pet oral care skin care hill cl
focus channel diversif includ new hill vet-bas digit
subscript platform farm feed similarli cl expand elmex
meridol distribut china e-commerc brazil pharmaci final cl
skin care brand pca skin eltamd fulli base recent
filorga acquisit close septemb see risk/reward profil
skincar categori expans well-balanc elta distributor connect china
possibl growth engin off-set challeng elsewher revenu margin
accret filorga contribut although skin care still rel small busi
cl see risk execut integr new busi
nascent skincar portfolio given high competit local foreign competitor
within highli popular categori
dissect us still challeng price come expens volum
tracked-channel us challeng cl shown chart
price increas spring summer off-set erod
volum trend last larg balanc year four-week
period end novemb growth turn neg despit lap
growth prior-year period bring question sustain continu
price initi sale cl top ten scan categori weak growth
four categori largest hand soap key categori like
toothpast remain neg total compani growth
chart cl us perform top categori mix
chart cl perform us track channel volatil
nielsen data last week period
estim cl underli categori weight cl exposur grow
pace although acknowledg cl increasingli sourc
sale outsid scan channel hill outsid scan channel
still view categori dynam potenti challeng cl execut
consist across portfolio recent trend show weak major categori
chart cl underli categori grow low-singl digit weight averag
cl under-perform categori us drive share loss
cl growth under-perform categori drive share loss recent
data indic trend continu even roll-out total sf note
cl start heavier market anticip need come
subsequ quarter support new exist initi
chart weight underli categori growth vs cl sale growth us
chart cl weight averag share declin sinc april
spend pet specialti still solid
cl hill busi sale strong follow relaunch scienc
diet prescript formul consider effort cl consum
concern pet diet expect solid growth sustain
chart hill solid pet specialti retail still grow
intern data debit/credit card spend pet specialti retail
high emerg market exposur better lt tougher manag st
cl highest exposur hpc person emerg market
vs core hpc averag histor key driver
faster organ sale growth recent compani number
challeng includ brazil macro challeng increas india grow prefer
natur well growth slowdown due rural market recent china
rise consum interest herbal/medicin brand
chart emerg vs develop market mix compani
chart growth develop vs emerg market
tabl summar cl manag commentari region
face challeng recent period variou phase recoveri brazil
china continu area concern although region improv late
innov increment distribut price result return organ sale
growth africa india recent china china cl process
reorient portfolio toward higher-growth premium product on-line includ
new innov brand via e-commerc leverag lead darli brand along
colgat brand bolster foothold market
tabl manag commentari challeng market signal work done posit sign still show
cl
averag sale price
overal share due sorriso colgat brand
total share
competitor reduc price significantli
categori
lap trucker strike
smaller competit crop compet
local tast knowledg market
inventori destock tradit channel
extend elmex pharmaci channel distribut
brazil
take price across toothpast given local competit
elect take strateg approach
price protex face colgat
took price saw volum come back
leverag darli brand higher share brand
name colgat push innov major restag darli darli reclaim top share spot
colgat total share
elmex well toothpast toothbrush soft
mouthwash
slowdown still double-digit
deliv first organ sale sinc
tabl manag commentari challeng market signal work done posit sign still show
cl
competitor grow significantli china
intens competit local player
reduct corpor tax rate
polit econom uncertainti
africa/eurasia local brand
plan return sustain profit growth
improv go-to-market capabl china-specif innov
colgat restag slate seek improv e-commerce
commerci effort focus behind local brand vedshakti
manag acknowledg work need done
speed go-to-market digit print packag
adapt rapidly-evolv price environ
focus premium push natur signific
price premium market
launch jv nigeria
focus faster-growth channel eurasia
launch elmex north africa meridol turkey
complet refocus fundament africa
elmex gain pt share on-line launch
contribut guide-down tax rate
initi sign encourag reflect higher share
reduc go-to-market lead time factor
colgat total share pt overal oral care
share flat
soft compar
best segment result sever year
nigeria jv contribut point growth
russia turkey africa mend
mitig inflat allevi extern pressur
pressur competit intens rais overal cost compet hpc
seen margin pressur across space cl except
margin contract net impact cost inflat reinvest
forecast gross oper margin respect
gross margin improv commod fx annual cl reliabl
fund growth program gener save off-set ultim see mute
margin expans gross margin bp better level
still well recent-best oper margin expect
minim lift bp three consecut year margin
contract well level compani
abl gener manag premium price mix shift initi hill could
offer lift margin see endeavor costli invest
take time solidifi event price could catalyz volum contract
chart expect cl gross oper margin moder
gross margin tough forecast slight expans
cl seen challeng gross margin year start year guid
subsequ lower quarter declin fy fx
commod mix pressur expect relent somewhat
cost program continu gener save along fx-relat price
oper expens like stay elev
like compani colgat need earn fund reinvest drive top-lin
growth earn reli promot ad spend eat profit
certainli abil flex ep deliveri howev believ colgat
still unsteadi posit need increas fund revenue-grow
initi show flex sometim enough off-set
lower po re-rat year
along much stapl particularli hpc sub-sector cl share appreci
share ytd close expect ep declin
year cl trade consensu ntm price-to-earnings averag absolut
term though discount histor trade rel hpc peer
share current trade nearli premium market premium
stapl though slight discount hpc given strength sector year
po repres target price-to-earnings high end histor level
believ adequ reflect cl balanc risk/reward go
chart cl ntm price-to-earnings expand ytd histor averag
chart cl ntm price-to-earnings premium
price-to-earnings rel
risk rate chang
growth could lower despit reserv colgat oper
landscap near medium term share elev valuat also
acknowledg strong track record strong brand stewardship pose risk
rate chang colgat need spend behind brand
roll premium innov could acceler continu push
momentum key categori geographi particular upsid potenti hill
especi given difficulti read brand due non-track channel although
view challeng across cl intern busi persist time
particularli china acknowledg outsiz effort key market like new
bake soda innov slate asia pacif market well cl china
share darli brand
market interest large-scal could gain momentum
discuss numer press report year colgat could interest
possibl candid given geograph reach high global market share
recent weak sever global stapl competitor could lead
colgat recent acquisit histori acquir could pose upsid risk
growth algorithm consid exampl favor categori dynam
underpin skincar moment colgat continu enjoy low leverag ratio
solid cash posit futur continu seem possibl follow pca skin
eltamd acquisit filorga acquisit earlier year
possibl market pivot back growth valu recent investor attent
pivot toward valu name valuat multipl risen clearli valu
trap market cl continu invest behind improv foot key
categori geographi inflect invest growth could establish
colgat compel stock choic although rotat valu stock
seem likeli invest trend year come organ sale
acceler could spur renew interest among investor colgat growth
sale
sale
sale
depreci amort
ni non-controlling interest
ni non-controlling interest
mo end decemb
sale
sale
sale
depreci amort
ni attribut non-controlling inter
price object base forward price-to-earnings ep estim
premium large-cap stapl reflect tougher oper environ
invest need despit acumen hpc time cl gener improv
sale growth demonstr abil manag difficult macro-
economic/curr environ recent result challeng key categori
geographi alreadi elev organ sale growth expect believ
valuat full level especi consid continu need reinvest
drive top-line
risk downsid increas price competit stronger us macro
volatil particularli emerg market risk upsid stronger em
perform significantli lower commod cost growth ahead categori
olivia tong cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
helen troy
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
